15May 2021
The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics

The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics

Heart failure is prevalent in those with type 2 diabetes and chronic kidney disease and is associated with significant mortality and morbidity. In the CREDENCE trial canagliflozin reduced the risk of hospitalization for heart failure (HHF) or cardiovascular (CV) death by 31%.

  • #endo-diabetology

Like

Save

Share